Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis. https://t.co/FgyoreY3s5
This study on effects of EGF blockade on atherosclerosis may have no relevance to cancer.
Interesting study showing EGFR blockade induces T cell anergy. Do any lung cancer gurus have thoughts on the relevance of this for attempts to make immunotherapy work in EGFR mut NSCLC? @n8pennell @LeciaSequist @Tony_Calles @GautschiOliver @JulienMazieres
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis. https://t.co/2N7rYiQXZN
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @CardioOncology: Can small molecular kinase inhibitors used in cancer be also effective in heart disease? Interesting that EGFR inhibito…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @CardioOncology: Can small molecular kinase inhibitors used in cancer be also effective in heart disease? Interesting that EGFR inhibito…
Can small molecular kinase inhibitors used in cancer be also effective in heart disease? Interesting that EGFR inhibitors are not really cardiotoxic! #CardioOnc @JACCJournals https://t.co/mThhgMNL60
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
RT @JACCJournals: A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://…
A common class of cancer medications (EGF-receptor inhibitors) may prove to be a target for heart disease. #JACC https://t.co/go4kOqeVZi @UParisDescartes @Inserm https://t.co/DyPxNO0o1K
EGF-Receptor Inhibition reduces #Atherosclerosis #Inflammation #Cardiology #Immunity @JACCJournals Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis https://t.co/aQI9QxdzxT https://t.co/qAe8l0w98F